This company has not started trading yet. The live 5-factor QL signal switches on automatically on its first session.
We are a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, COPD, and atopic dermatitis. We estimate these diseases collectively represent a $60 billion peak market opportunity for biologic therapies, as we believe the majority of patients eligible to receive biologic treatment for these diseases remain untreated.
From Windward Bio Group AG's Form F-1/A filed with the SEC on 2026-11-09. The issuer's own words — QuantLogix does not paraphrase it.
We currently intend to use the net proceeds from this offering and the concurrent private placement, together with our existing cash, cash equivalents and marketable securities for the following purposes: ∎ Approximately $217.5 million to $227.5 million to fund (i) the completion of our ongoing POLARIS-1 Phase 2/3 trial and a confirmatory POLARIS-2 Phase 3 trial of WIN378 in asthma; (ii) the completion of our ongoing SIRIUS Phase 2 trial of WIN378 in COPD; and (iii) related research and development activities, including clinical development, regulatory…
From Windward Bio Group AG's Form F-1/A filed with the SEC on 2026-11-09. Quoted from the prospectus.
The audited financial statements for this issuer are in its Form F-1/A filed 2026-11-09. QuantLogix only publishes figures it can read directly from the filing.
From Windward Bio Group AG's Form F-1/A filed with the SEC on 2026-11-09. Extraction is deterministic — the same filing always produces the same score; 758k characters of the document were scanned. Technology signals are lexical indicators, not a technical audit. Not investment advice; the debut itself will be this score's first grade.
Deal terms come from the public IPO calendar and change up to pricing — an expected date reads “to be announced” until the underwriters set it, and a range is not a final price. Implied market cap and float are arithmetic on those disclosed terms. Nothing on this page is a forecast or a recommendation.